Navigation Links
Preclinical Data Demonstrate Ability to Regenerate an Entire Bladder With Tengion Neo-Bladder Replacement(TM)
Date:5/19/2008

Preclinical Results Show Neo-Bladder Replacement Structurally Similar to Native Bladder by Six Months; Data Presented at May 18 Press Briefing and

Poster Session

ORLANDO, Fla. and EAST NORRITON, Pa., May 19 /PRNewswire/ -- Tengion, Inc., a clinical stage biotechnology company focused on the development of neo-organs and neo-vessels, presented preclinical efficacy data for its Tengion Neo-Bladder Replacement(TM) at the Annual Meeting of the American Urological Association (AUA) in Orlando, Florida on May 18, 2008. The data were presented by Tim Bertram, D.V.M., Ph.D., Senior Vice President, Science and Technology of Tengion, during both a poster session and a press briefing sponsored by the AUA.

"In this well-established preclinical model, the Neo-Bladder Replacement was able to achieve functional recovery and a regenerative response that emulated the native bladder," said Dr. Bertram. "These data join the existing body of information from the preclinical studies of our first product candidate, the Tengion Neo-Bladder Augment, and underscore the promise and potential of our Autologous Organ Regeneration Platform as a foundation for our pipeline of regenerative medicine products."

The preclinical study presented at AUA was a six-month, single-arm study to evaluate the application of Tengion's technology to regenerate an entire urinary bladder. Neo-Bladder Replacements were produced from autologous bladder cells seeded onto a biodegradable scaffold and were then surgically implanted into 23 large mammals.

In this study:

-- Tengion's Neo-Bladder Replacement was able to regenerate an entire

urinary bladder within six months after implantation

-- The regenerated bladder demonstrated near-baseline capacity and

cystography by six months after implantation

-- The regenerated bladder wall structure consisted of three layers:

urothelium, muscle, and serosa by approximately two months after

implantation

-- The regenerated bladder wall showed near native pharmacological and

electrophysiological functional responses by six months after

implantation

Tengion is currently conducting a GLP study of its Neo-Bladder Replacement to support a planned request to the FDA in the near future to initiate human clinical trials in 2009. Additionally, Tengion is currently conducting three Phase 2 clinical trials of its Neo-Bladder Augment at 12 leading academic medical centers across the United States: one in children with neurogenic bladder due to spina bifida, one in adults with neurogenic bladder due to spinal cord injury and one in adult patients with overactive bladder (OAB) and urge incontinence.

About Tengion

Tengion, a clinical stage biotechnology company, focuses on developing, manufacturing and commercializing human neo-organs and neo-tissues using our Autologous Organ Regeneration Platform(TM). Tengion uses biocompatible materials and a patient's own (autologous) cells to create neo-organs or neo- tissues that are designed to catalyze the body's innate ability to regenerate. Tengion's product candidates may ultimately address the most critical problems facing organ and tissue failure patients, enabling people to lead healthier lives without donor transplants or the side effects of related therapies. For more information on the company and current clinical trials, visit Tengion online at: http://www.tengion.com.


'/>"/>
SOURCE Tengion, Inc.
Copyright©2008 PR Newswire.
All rights reserved

Related medicine technology :

1. Quark Pharmaceuticals, Inc. Presented Positive Preclinical Results of Systemic RNAi Compound for Acute Renal Failure (ARF)
2. Lpath Demonstrates Preclinical Efficacy of Lpathomab(TM) and Initiates Humanization Process
3. Siemens Preclinical Imaging System Helps The Methodist Hospital in Houston Further Its Research Mission
4. Anadys Pharmaceuticals Presents Preclinical Results on ANA598, a Non-Nucleoside Inhibitor of the NS5B Polymerase, at the 14th International Symposium on Hepatitis C Virus and Related Viruses
5. NicOx and Ferrer Present Promising Clinical and Preclinical Results in Dermatology
6. Isis Reports Preclinical Data Supporting Liver Safety of ISIS 301012
7. Preclinical Data on Lead MEK Inhibitor, RDEA119, to be Presented at the 2007 AACR-NCI-EORTC International Conference on Molecular Targets and Cancer Therapeutics
8. KineMed Presents Preclinical Data for Investigational Agent Demonstrating Neurogenesis and Confirming Improvements in Behavioral Model
9. Tezampanel, TorreyPines Therapeutics Lead Compound, Reduced Muscle Spasticity and Rigidity in Preclinical Study Conducted at University of California, San Diego
10. Telik Announces Presentation of Preclinical Data on Dual Inhibitors of Aurora Kinases and VEGFR2
11. CorNova Preclinical Results of Valecor Platinum(TM) Coronary Stent Studies Presented at TCT 2007 Conference
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:8/15/2017)... Inc., the creator of the drug Truveta for the treatment ... IPO. The United States spends approximately ... prescription epilepsy drug being $450.00-$1200.00 for a one month supply. ... AXIUM PHARMACEUTICALS, INC ... is the fact that Americans spent $42 billion on anxiety medications last ...
(Date:8/11/2017)... , Aug. 11, 2017 DarioHealth Corp. (NASDAQ: ... health and big data solutions, today announced that it ... August 14 and host a conference call at 9:00am ... operating and financial results and its strategy and outlook ... hosted by Erez Raphael , Chief Executive Officer, ...
(Date:8/7/2017)... 7, 2017 Insightin Health, provider of ... and engagement, announced the selection of Michael ... Development, effective as of February 2017. In this role, ... strategy for our clients. Wood brings with him ... and business analytics within the healthcare industry. Wood ...
Breaking Medicine Technology:
(Date:8/17/2017)... ... ... Pot Valet is a leading provider of premium medical-grade cannabis in California. ... soon, every state in the country, the company offers patients safe, legal, and discreet ... , According to Pot Valet, all California patients have the legal right to ...
(Date:8/17/2017)... (PRWEB) , ... August 17, 2017 , ... ... Great Employers , an international competition, were announced today. The awards recognize the ... and suppliers who help to create and drive great places to work. , ...
(Date:8/16/2017)... , ... August 16, 2017 , ... The next Patient ... being accepted. , Students who successfully complete the seven-week long Patient Care Academy ... Assistant (CNA). The average starting salary for a CNA in Kalamazoo is $24,428.* , ...
(Date:8/16/2017)... Houston, Texas (PRWEB) , ... August 16, 2017 , ... ... Community Credit Union's Stars in the Classroom and will win a visit by a ... in grades K-12 who are at least five years old can visit texanschecking.com/stars to ...
(Date:8/16/2017)... ATLANTA, Georgia (PRWEB) , ... August 16, 2017 ... ... practice in Atlanta, opened their doors. They celebrate 30 years in business this ... to create an up-to-date, inviting, tranquil space to serve their patients. , ...
Breaking Medicine News(10 mins):